Terufumi Kato

17PUBLICATIONS
130CO-AUTHORS
Tumour immunologyMolecular targetsPredictive and prognostic markersCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 15, 2026
Clinical and Imaging Features of Tepotinib-Induced Interstitial Lung Disease in the Post-Marketing Setting in Japan.

|Jun 02, 2026
Clinical Utility of Comprehensive Genomic Profiling for Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.

|Mar 09, 2026
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Jhanelle E Gray, Konstantin Laktionov, Sang-We Kim

|Jun 27, 2025
Safety and effectiveness of tepotinib in patients with unresectable, advanced or recurrent non-small cell lung cancer with METex14 skipping alterations: post-marketing surveillance in Japan.

Terufumi Kato, Tatsuya Ogura, Masashi Sato

|May 23, 2025
KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.

Takashi Kijima, Terufumi Kato, Yasushi Goto

|Apr 16, 2025
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.

Satoru Miura, Hiroshi Tanaka, Toshihiro Misumi

Pageof 3

Frequent Collaborators

4 joint publications

Yi-Long Wu

3 joint publications

Shoichi Kuyama

3 joint publications

Konstantin Laktionov

2 joint publications

David Planchard